$TMO

CASPER MARC N sold $5.7M of TMO

CASPER MARC N (Chairman & CEO) sold 10,000 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $574.47 ($571.05–$579.90, $5.74M total) across 9 trades on 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 7, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (10,000 shares across 9 trades, $5.74M total) and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, primary-source datapoint on insider selling, but the 10b5-1 designation typically limits interpretive value for price action.

03

What to watch

Traders may also consider whether the insider’s remaining holdings (123,925 shares after sale) and any prior sale cadence suggest a planned schedule rather than new information.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-08-07)

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by its Chairman & CEO.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher CEO/C chairman Casper Marc N sold 10,000 shares in an open-market transaction totaling about $5.74M at $571.05–$579.90.

Expected impact

Likely limited near-term impact; any reaction is typically muted when the filing states a 10b5-1 plan.

Evidence & confidence

The filing provides transaction size, price range, and confirms a pre-arranged 10b5-1 plan, which traders often discount versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • CASPER MARC N

    Chairman & CEO who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DALMed

CNBC’s ‘Final Trades’: Delta Air, Target, Thermo Fisher Scientific - Delta Air Lines (NYSE:DAL)

CNBC's 'Final Trades' featured picks from analysts, including Delta Air Lines (DAL) for its strong Q2 earnings, Thermo Fisher Scientific (TMO) for its raised FY2026 guidance, and Target (TGT) for its better-than-expected Q2 results. Interactive Brokers (IBKR) was also mentioned for its new Latin America funding solution. DAL +1.4%, TMO -0.1%, TGT -3.8%, IBKR +5.5%.

$BIIBMed

Eyes on Asia: Tanabe Pharma, KYAN Technologies, Biogen

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.